Community Oncology Alliance launches Advanced Practice Provider Network

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE COMMUNITY ONCOLOGY ALLIANCE launched the Advanced Practice Provider Network, for oncology nurse practitioners, physician assistants and others.

The network consists of a private, peer-to-peer-only information sharing website and listserv; monthly conference calls to review important practice issues and discuss solutions; and opportunities for in-person meetings. Participation in the network is open and free of charge to all qualified advanced practice providers. Vendors and other industry representatives are not allowed access to join this private network.

The network’s goal is to keep members up to date on the latest news and developments, such as patient support strategies; health reform initiatives; the newest drugs and therapies; and strengthening advanced provider leadership roles in practices.

The network is led and organized by advanced practice providers in community practices with technical support from COA. The co-chairs are Sarah Alexander, nurse practitioner at Lake Norman Oncology in Mooresville, N.C.; and Diana Youngs, nurse practitioner at North Shore Hematology Oncology Associates in Long Island, N.Y.

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login